It can be overwhelming for patients to remember all the information they are told during an office visit. Download resources that may be helpful in discussing prostate cancer and genomic testing with your patients.
Oncotype DX Genomic Prostate Score (GPS)
- A genomic test measures the expression of genes within a sample of tumor tissue.
- The Oncotype DX GPS test is a genomic test, and the results can help determine how aggressive the patient’s cancer is.
For patients who have been recently diagnosed with low-, intermediate-, and high-risk
prostate cancer and have not yet begun treatment, the Oncotype DX GPS might be appropriate to help guide management decisions. The GPS assay is not intended for men with advanced prostate cancer.
Preparing for test results
Oncotype DX Genomic Prostate Score - Understanding the Results
What your patients can prepare for prior to an appointment with you to discuss their Oncotype DX Genomic Prostate Score results.
Learn more about interpreting the GPS report results
A guide to the Oncotype DX GPS for men newly diagnosed with early-state prostate cancer.